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OBJECTIVE — To study the association between peri-conceptional A1C and serious adverse
pregnancy outcome (congenital malformations and perinatal mortality).
RESEARCH DESIGN AND METHODS — Prospective data were collected in 933 sin-
gleton pregnancies complicated by type 1 diabetes.
RESULTS — The risk of serious adverse outcome at different A1C levels was compared with
the background population. The risk was signiﬁcantly higher when peri-conceptional A1C
exceeded6.9%,andtherisktendedtoincreasegraduallywithincreasingA1C.WomenwithA1C
exceeding 10.4% had a very high risk of 16%. Congenital malformation rate increased signiﬁ-
cantly at A1C above 10.4%, whereas perinatal mortality was increased even at A1C below 6.9%.
CONCLUSIONS — These results support recent guidelines of preconceptional A1C levels
7% in women with type 1 diabetes.
Diabetes Care 32:1046–1048, 2009
R
ecently,guidelinesformanagement
of pregnancy in women with pre-
gestational diabetes have recom-
mended pregestational A1C values
7.0% (1,2) and 6.1% (3). Previous
studieshavereportedinformationofearly
A1Cincluding116–691pregnancies(4–
10).Weaimedtostudywhetherthereisa
threshold value for peri-conceptional
A1Cinwomenwithtype1diabetesbelow
which the risk of serious adverse preg-
nancy outcome (congenital malformation
and perinatal mortality) is not increased.
RESEARCH DESIGN AND
METHODS— During 1993–1999,
pregnancies in women with type 1 diabe-
tes were prospectively reported from
eight centers to a central registry in the
Danish Diabetes Association (11). Evalu-
ated by alternative local data sources, the
coverage was 75–93% and clinical data
showed no differential selection. Stan-
dard guidelines included prepregnancy
counseling, but only 58% attended this
(11). A dose of 400 g folic acid was rec-
ommended in early pregnancy. All pa-
tients gave informed consent, and the
local ethics committees approved the
study.
Inclusion criteria were as follows: de-
livery after 24 completed weeks (n 
1,215) or termination before 24 weeks
because of ultrasound-veriﬁed malforma-
tions (n  3). Multiple and recurrent
pregnancies were excluded, leaving 933
pregnancies. Of these, 784 had complete
data on preconceptional A1C, whereas
ﬁrst-trimester A1C was used as a surro-
gatein149cases.Backgroundpopulation
data were based on 70,089 deliveries re-
corded by the Danish Health Board in
1995 (11).
Four different local A1C assays were
prospectively subjected to centralized
quality control: Mono-S HPLC method,
Boehringer Mannheim Tinaquant, Roche
Unimate, and Abbott IMx. A standard as-
say (Mono-S) based on nonpregnant sub-
jects (5.4  1.0% [mean  2 SD]) was
used for reference. Correction was made
in 50% by multiplying A1C with a cor-
rection factor (mean of reference values
for the standard assay divided by mean of
the reference values for the given assay).
The z scores were derived from the stan-
dard assay. Corresponding z scores and
A1C values are shown in Table 1.
Perinatal mortality was intrauterine
death at 24 weeks or death during the
ﬁrst 7 days of life. Major congenital mal-
formations were those responsible for
death, causing a signiﬁcant future handi-
cap or requiring major surgery, while mi-
nor congenital malformations comprised
the remainder (8). Congenital malforma-
tions were assessed during hospital stay.
Data were analyzed by STATA 9.0
(Stata Corporation) and are given as per-
cent or relative risk and 95% CIs. The 
2
test was used for comparing outcomes at
different A1C levels.
RESULTS— Participants were 28.6 
4.8 years old with a prepregnancy BMI of
23.6  3.5 kg/m
2; duration of diabetes
was12.37.9years,andtimeforadmis-
sion was 9.6  3.5 weeks (means  SD).
All women were Caucasian. A total of 71
infants had serious adverse outcome: 45
congenital malformations (including 23
major) and 31 perinatal deaths (5 with
major malformations).
The relative risks of serious adverse
outcome at increasing levels of peri-
conceptional A1C compared to the back-
groundpopulationarepresentedinTable
1. The risk was increased when A1C ex-
ceeded6.9%andtendedtoincreasegrad-
ually with increasing A1C. Congenital
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at A1C above 10.4%, whereas perinatal
mortality was increased even at an A1C
below 6.9%.
CONCLUSIONS — To our knowl-
edge, the present study is the largest pro-
spective population-based study in
pregnant women with type 1 diabetes
with information of peri-conceptional
A1C. Denmark is a small country with an
overall consensus on prenatal care, and
with the central validation of the A1C
analysis, we ﬁnd our results representa-
tive and valid.
We used a reference based on A1C
values outside pregnancy, and although
A1C has been shown to decline during
pregnancy (12), this is not until later
stages of gestation.
The3.9%riskofinfantswithcongen-
ital malformations in diabetic women
withA1Czscores3(A1C6.9%)didnot
differ signiﬁcantly from the 2.8% back-
ground population risk. This can be due
to a true biologic relationship but could
also be explained by lack of power (only
21%),sincethestudywasnotdesignedto
speciﬁcally address this association. It is
therefore still possible that no safe A1C
threshold exists above the upper normal
range. The risk of congenital malforma-
tion at A1C z scores above 10 (A1C
10.4%) was fourfold and signiﬁcantly in-
creased compared with the background
population. Perinatal mortality was in-
creased also when z score was 3, most
likely reﬂecting the well-known fact that
factors other than hyperglycemia, such as
smoking, nephropathy, preeclampsia,
preterm delivery, and A1C in late preg-
nancy, affect perinatal mortality.
Suhonen et al. (9) studied 709 off-
spring of type 1 diabetic women and
foundanincreasedriskofcongenitalmal-
formationsatslightlyraisedA1Cvalues(z
scores of 2.0–5.9). Analyzing 573 type 1
diabetic pregnancies, Nielsen et al. (5) re-
ported a dose-dependent association be-
tween the risk for adverse pregnancy
outcome (abortion, stillbirth, neonatal
death, or major congenital malformation)
and ﬁrst trimester A1C without any
threshold value. Hanson et al. (7) exam-
ined532womenwithtype1diabetesand
222controlsubjects,demonstratingasig-
niﬁcant increase in congenital malforma-
tion and spontaneous abortion at A1C z
scores 8.
The risk of the composite serious ad-
verse outcome among diabetic women in
our study was higher than in the back-
ground population when peri-concep-
tional A1C z scores exceeded three, but
again, it cannot be ruled out that the risk
at A1C z scores 3 would have been sig-
niﬁcantly increased in a larger study. As
illustrated in Table 1, the risk of serious
adverse outcome increased abruptly at
A1C z score 10, suggesting three levels
ofrisk:zscore3(lowrisk);zscore3–10
(intermediate risk), and z score 10
(high risk). Women attending prepreg-
nancy care have signiﬁcantly lower A1C
levels than nonattenders (13), indicating
that improved prepregnancy glycemic
control is the target for reducing the risk
ofseriousadversediabeticpregnancyout-
comes. The experience of many clinicians
dealing with planning of pregnancy in
women with type 1 diabetes is that A1C z
score 3 is often obtainable and associ-
ated with a limited number of mild hypo-
glycemic episodes.
Inconclusion,theresultsofthisstudy
supportarecommendationofpreconcep-
tional A1C levels 7% in women with
type 1 diabetes, emphasizing the impor-
tance of prepregnancy counseling.
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